Literature DB >> 10705026

Radiation doses to the cell nucleus in single cells and cells in micrometastases in targeted therapy with (131)I labeled ligands or antibodies.

T Hartman1, H Lundqvist, J E Westlin, J Carlsson.   

Abstract

PURPOSE: The aim of this study was to theoretically investigate how the radiation dose to cell nuclei depends on the subcellular position of (131)I. The influence of the size of the cells and crossfire irradiation in clusters of cells was also studied. METHODS AND MATERIAL: Using data describing the dose rate around a point source of (131)I, we calculated the dose distributions inside and around cell models of different sizes. The assumed positions of (131)I were on the cellular or nuclear membrane, in the cytoplasm, in the nucleus, or spread in the whole cell. The mean doses to the nucleus of the targeted cell and to the nuclei of its neighbors were calculated using the dose distributions.
RESULTS: The dose distributions inside a single targeted cell showed very different distribution profiles depending on the subcellular position of the (131)I. Targeting the nucleus instead of the cellular membrane could increase the dose to the nucleus 10-fold. Crossfire irradiation can be the major contributor to the nuclear dose in clusters of more than six cells.
CONCLUSIONS: Dosimetry without microscopic considerations is inadequate for targeted radionuclide therapy of disseminated or clustering tumor cells exposed to (131)I. Therapeutic doses could be achieved, even in single cells, when (131)I was positioned near, or inside the cell nucleus, or when the clusters were large enough.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10705026     DOI: 10.1016/s0360-3016(99)00476-9

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  Calculation of electron dose to target cells in a complex environment by Monte Carlo code "CELLDOSE".

Authors:  Elif Hindié; Christophe Champion; Paolo Zanotti-Fregonara; Domenico Rubello; Nicole Colas-Linhart; Laura Ravasi; Jean-Luc Moretti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-09       Impact factor: 9.236

Review 2.  Planning for intracavitary anti-EGFR radionuclide therapy of gliomas. Literature review and data on EGFR expression.

Authors:  J Carlsson; Z P Ren; K Wester; A L Sundberg; N E Heldin; G Hesselager; M Persson; L Gedda; V Tolmachev; H Lundqvist; E Blomquist; M Nistér
Journal:  J Neurooncol       Date:  2006-03       Impact factor: 4.130

3.  Glypican-3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy.

Authors:  Hirofumi Hanaoka; Tadanobu Nagaya; Kazuhide Sato; Yuko Nakamura; Rira Watanabe; Toshiko Harada; Wei Gao; Mingqian Feng; Yen Phung; Insook Kim; Chang H Paik; Peter L Choyke; Mitchell Ho; Hisataka Kobayashi
Journal:  Mol Pharm       Date:  2015-05-19       Impact factor: 4.939

4.  Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF.

Authors:  Asa Liljegren Sundberg; Ylva Almqvist; Anna Orlova; Erik Blomquist; Holger J Jensen; Lars Gedda; Vladimir Tolmachev; Jörgen Carlsson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-08-21       Impact factor: 9.236

5.  Synthesis and cellular studies of polyamine conjugates of a mercaptomethyl-carboranylporphyrin.

Authors:  N V S Dinesh K Bhupathiraju; M Graça H Vicente
Journal:  Bioorg Med Chem       Date:  2012-11-17       Impact factor: 3.641

6.  Tumor-cell targeted epiderimal growth factor liposomes loaded with boronated acridine: uptake and processing.

Authors:  Erika Bohl Kullberg; Marika Nestor; Lars Gedda
Journal:  Pharm Res       Date:  2003-02       Impact factor: 4.200

7.  Requirements regarding dose rate and exposure time for killing of tumour cells in beta particle radionuclide therapy.

Authors:  Jörgen Carlsson; Veronika Eriksson; Bo Stenerlöw; Hans Lundqvist
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-05-23       Impact factor: 9.236

8.  225Ac-rHDL Nanoparticles: A Potential Agent for Targeted Alpha-Particle Therapy of Tumors Overexpressing SR-BI Proteins.

Authors:  Tania Hernández-Jiménez; Guillermina Ferro-Flores; Enrique Morales-Ávila; Keila Isaac-Olivé; Blanca Ocampo-García; Liliana Aranda-Lara; Clara Santos-Cuevas; Myrna Luna-Gutiérrez; Laura De Nardo; Antonio Rosato; Laura Meléndez-Alafort
Journal:  Molecules       Date:  2022-03-27       Impact factor: 4.411

9.  17AAG-induced internalisation of HER2-specific Affibody molecules.

Authors:  Lovisa Göstring; Sture Lindegren; Lars Gedda
Journal:  Oncol Lett       Date:  2016-08-10       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.